Pharmacology/Pharmaceutical Industry | Page 61 of 172 | Links Medicus Content Curation & Alerts in Medicine

RCT: In critically ill patients with Covid-19, therapeutic anticoagulation with heparin did not result in improved outcomes compared to usual-care pharmacologic thromboprophylaxis.

5 Aug, 2021 | 09:04h | UTC

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 – New England Journal of Medicine

Editorial: Surviving Covid-19 with Heparin?

Commentaries:

Full-dose blood thinners reduce the need for organ support in moderately ill COVID-19 patients, but not in critically ill patients – National Institutes of Health

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t – TCTMD

Commentary on Twitter

Anticoagulation did not improve hospital survival in critically Ill patients with #COVID19. https://t.co/E8RXE01jbF pic.twitter.com/9idGxgbUas

— NEJM (@NEJM) August 4, 2021

RCT: Subcutaneous REGEN-COV antibody combination prevented symptomatic Covid-19 infection in previously uninfected household contacts of infected persons.

5 Aug, 2021 | 09:01h | UTC

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 – New England Journal of Medicine

RCT: Bamlanivimab plus Etesevimab reduce mortality and hospitalization in ambulatory patients with early Covid-19 (within 3 days of a positive test) who are at risk for clinical deterioration (i.e., older people, obese, diabetics, immunocompromised, with CV disease).

[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.

Commentary on Twitter

Subcutaneous REGEN-COV prevented symptomatic #COVID19 and asymptomatic #SARSCoV2 infection in previously uninfected household contacts. https://t.co/rRNFTjS9hX pic.twitter.com/B7qXeyWKUb

— NEJM (@NEJM) August 4, 2021

Covid: WHO calls for booster pause to vaccinate poorer nations.

5 Aug, 2021 | 08:59h | UTC

Covid: WHO calls for booster pause to vaccinate poorer nations – BBC

Myocarditis and pericarditis after vaccination for COVID-19.

5 Aug, 2021 | 08:57h | UTC

Myocarditis and Pericarditis After Vaccination for COVID-19 – JAMA

Analysis finds benefits of COVID-19 vaccination outweigh risks of rare cases of myocarditis.

CDC: Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients – “Continued use of mRNA COVID-19 vaccines in all recommended age groups will prevent morbidity and mortality from COVID-19 that far exceed the number of cases of myocarditis expected”.

Case Series: Myocarditis following immunization with mRNA COVID-19 vaccines.

CDC: mRNA vaccines are likely linked to cases of myocarditis and pericarditis – 1,226 cases of myocarditis or pericarditis have been reported mostly in people under 30.

Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.

5 Aug, 2021 | 08:33h | UTC

Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls – New England Journal of Medicine

Visual abstract: Risdiplam-Treated Infants with Type 1 SMA vs. Historical Controls

Antimicrobial stewardship in the ICU in COVID times: the known unknowns.

4 Aug, 2021 | 09:16h | UTC

Antimicrobial stewardship in the ICU in COVID times: the known unknowns – International Journal of Antimicrobial Agents

IDSA Updated Covid-19 Guidance: Co-Infection and Antimicrobial Stewardship – “bacterial coinfections with SARS-CoV-2 infection are relatively infrequent (likely occurring in less than 10% of hospitalized COVID-19 patients)”.

Antimicrobial stewardship in ICUs during the COVID-19 pandemic: back to the 90s?

Another study shows a high frequency of antibiotic use among patients hospitalized with Covid-19 (85.2%), despite low rates of confirmed secondary bacterial infections.

Too many COVID-19 patients get unneeded ‘just in case’ antibiotics

RCT: Text-message reminders can increase COVID-19 vaccinations.

4 Aug, 2021 | 09:12h | UTC

Behavioral Nudges Increase COVID-19 Vaccinations – Nature

Commentaries:

Text-message ‘nudges’ can encourage holdouts to get COVID vaccination, study finds – UCLA

Text reminders boost vaccine appointments – Carnegie Mellon University

Commentary on Twitter

Sometimes the tools that actually work in public health are profoundly boring. Here, a text message reminder system is shown in a randomized trial to increase vaccine uptake. Years of HIV adherence research has shown the value of simple nudges like this.https://t.co/1ndpnQ6Ha6 https://t.co/Gltll8DTJ4

— Natalie E. Dean, PhD (@nataliexdean) August 3, 2021

Cannabis and Cannabinoid Analgesia position statement – “Due to the lack of high-quality clinical evidence, the IASP does not currently endorse general use of cannabis and cannabinoids for pain relief.”

4 Aug, 2021 | 09:07h | UTC

International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia position statement – Pain

RCT: Routine treatment with fluoxetine does not reduce the incidence of depression after stroke.

4 Aug, 2021 | 08:56h | UTC

Depression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery: The AFFINITY Randomized Clinical Trial – JAMA Neurology (free for a limited period)

Editorial: Poststroke Selective Serotonin Reuptake Inhibitors—Do They Work for Anything? (free for a limited period)

[Abstract Only] Randomized trial: Fluoxetine does not improve functional recovery after acute stroke

Randomized Trial: Effects of Fluoxetine on Functional Outcomes After Acute Stroke

RCT: Midodrine can reduce the recurrence of vasovagal syncope.

4 Aug, 2021 | 08:54h | UTC

Midodrine for the Prevention of Vasovagal Syncope: A Randomized Clinical Trial – Annals of Internal Medicine

Commentary: Midodrine Cuts Recurrent Syncope in Young, Healthy Patients – HealthDay

Summary for patients: Summary for Patients: Midodrine to Prevent Fainting – Annals of Internal Medicine

Commentary on Twitter

New research out in Annals found that midodrine reduces fainting recurrence for younger patients with frequent #fainting spells https://t.co/D1crZ97AU2. pic.twitter.com/pZGEoERai6

— Annals of Int Med (@AnnalsofIM) August 3, 2021

RCT: Pimavanserin in dementia-related psychosis.

3 Aug, 2021 | 02:06h | UTC

Trial of Pimavanserin in Dementia-Related Psychosis – New England Journal of Medicine

How to safely dispose of medication.

3 Aug, 2021 | 01:55h | UTC

How to safely dispose of medication – Medical News Today

Opinion | Should pregnant women have a COVID vaccine? The evidence says it’s safe and effective.

2 Aug, 2021 | 00:28h | UTC

Should pregnant women have a COVID vaccine? The evidence says it’s safe and effective – The Conversation

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

2 Aug, 2021 | 00:31h | UTC

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM)

Additional reading:

Practice Advisory: COVID-19 Vaccination Considerations for Obstetric-Gynecologic Care

COVID-19 Vaccines and Pregnancy: Conversation Guide for Clinicians

Commentaries:

Obstetrician groups recommend COVID vaccine during pregnancy – Associated Press

Statements By Obstetrics Societies Strongly Advise Covid-19 Vaccinations For Pregnant Women – Forbes

Commentary on Twitter

Pregnant? ACOG and @MySMFM now recommend #COVID19 vaccination of pregnant individuals and urge our members to recommend that pregnant patients #GetVaccinated. The #covidvaccine is the best tool we have to save lives and end the pandemic: https://t.co/pUbLqqkKym #VaccinesWork pic.twitter.com/Ef2MOPv27L

— ACOG (@acog) July 30, 2021

What every intensivist should know about Tocilizumab.

2 Aug, 2021 | 00:25h | UTC

What every intensivist should know about Tocilizumab – Critical Care

Tocilizumab in COVID-19 therapy: who benefits, and how?

A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19.

M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”.

RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less.

M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.

COVID boosters for wealthy nations spark outrage.

2 Aug, 2021 | 00:21h | UTC

COVID boosters for wealthy nations spark outrage – Nature

Scientists Grapple with Question of COVID-19 Vaccine Booster, as Some Countries Push Ahead.

2 Aug, 2021 | 00:19h | UTC

Scientists Grapple With Question of COVID-19 Vaccine Booster, as Some Countries Push Ahead – Health Policy Watch

Investigation: FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway.

2 Aug, 2021 | 00:09h | UTC

FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway – The BMJ

News release: Investigation finds nearly half of drugs granted FDA ‘fast track’ approval lack proven clinical benefit – The BMJ

Commentary: Over 100 Drugs Given Speedy Approvals Still Lack Proof of Clinical Efficacy – MedPage Today (free registration required)

Guideline summary: A Multidisciplinary collaborative approach to retinal toxic effects screening for patients taking antimalarials.

2 Aug, 2021 | 00:03h | UTC

A Multidisciplinary Collaborative Approach to Retinal Toxic Effects Screening for Dermatology Patients Taking Antimalarials – JAMA Dermatology (free for a limited period)

Original Guidance: Joint Statement: Hydroxychloroquine use with respect to retinal toxicity

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

30 Jul, 2021 | 12:14h | UTC

COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis – National Institute for Health and Care Excellence

News release: NICE publishes new rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination – National Institute for Health and Care Excellence

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

30 Jul, 2021 | 12:12h | UTC

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know – Blood

Israel to offer 3rd COVID booster shot to older citizens.

30 Jul, 2021 | 11:57h | UTC

Israel to offer 3rd COVID booster shot to older citizens – Associated Press

ASCO Guideline Update: Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer.

30 Jul, 2021 | 11:51h | UTC

Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update – Journal of Clinical Oncology

RCT: Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer.

30 Jul, 2021 | 11:43h | UTC

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer – New England Journal of Medicine

Commentary on Twitter

In postmenopausal women with hormone-receptor-positive breast cancer who had 5 yrs of AI, extending adjuvant endocrine therapy by 5 years provides no benefit over a 2-year extension but is associated with a greater risk of bone fracturehttps://t.co/YDxeQVu8B9

— K Pavithran (@drkpavithran) July 29, 2021

RCT: Among pregnant women with primary CMV infection diagnosed before 24 weeks’ gestation, monthly infusion of CMV hyperimmune globulin did not prevent congenital cytomegalovirus infection.

30 Jul, 2021 | 11:42h | UTC

A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Hyperimmune Globulin Fails to Prevent Congenital CMV – Physician’s Weekly

Stay Updated in Your Specialty